Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis

Osimertinib is the only Food and Drug Administration‐approved third‐generation epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitor (TKI). A meta‐analysis was performed to aggregate the mixed results of published clinical trials to assess the efficacy and safety of osimertinib. A system...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Lilan, Fan, Junsheng, Qian, Ruolan, Luo, Peng, Zhang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590181/
https://www.ncbi.nlm.nih.gov/pubmed/30613959
http://dx.doi.org/10.1002/ijc.32097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590181/
https://www.ncbi.nlm.nih.gov/pubmed/30613959
http://dx.doi.org/10.1002/ijc.32097

Ejemplares similares